Genetic predisposition to blood sugar spikes linked to 69% higher Alzheimer's risk

A team of researchers from the University of Liverpool has identified a genetic link between how the body handles blood sugar after meals and the risk of developing Alzheimer's disease. The finding, published in Diabetes, Obesity and Metabolism, suggests that people carrying genetic variants associated with sharper post-meal glucose spikes face a 69% higher likelihood of developing the disease compared to those without these variants.

The study analyzed genetic data from nearly 358,000 people enrolled in the UK Biobank, a long-running health study that began recruiting participants in 2006. Rather than measuring actual blood sugar levels, the researchers used a method called Mendelian randomization, which examines specific genes known to influence glucose response. This approach has a key advantage: it isolates the genetic effect from confounding factors like diet, exercise, or overall health status that might otherwise skew the results. The researchers looked for genetic variants tied to blood sugar levels two hours after eating, fasting blood sugar, insulin resistance, and fasting insulin levels.

What emerged from the data was striking in its specificity. Genetic predisposition to higher glucose levels after meals correlated strongly with increased Alzheimer's risk. But fasting blood sugar, fasting insulin levels, and insulin resistance showed no such association. This distinction matters because it points to something particular about how the body responds to food rather than baseline metabolic function. Andrew Mason, one of the study's lead researchers, noted that the genetic variants linked to larger post-meal glucose spikes appear in roughly 40% of the population. These variants influence how efficiently the body handles glucose after eating—affecting insulin sensitivity and the timing and strength of insulin release.

The mechanism behind this connection remains a mystery. When researchers examined brain scans from study participants, they found no visible structural changes or damage that would typically mark Alzheimer's disease. This suggests the link between blood sugar spikes and dementia risk may not operate through the loss of brain cells or their connections, the hallmark pathology usually seen in the disease. Instead, researchers hypothesize several possible pathways: inflammatory responses that damage small blood vessels, brain inflammation triggered by high blood sugar, or damage to the blood-brain barrier caused by metabolic dysfunction.

The findings come with important caveats. When researchers attempted to replicate the results using a different genetic dataset, they were unsuccessful. One of the study's authors, Nasri Fatih, explained that the two datasets defined Alzheimer's differently—the second study counted some people as cases if they reported a parent with dementia—which could have obscured a real effect. Additionally, the UK Biobank participants tend to be healthier, better educated, and more health-conscious than the general population. The analysis also focused only on white British participants due to small numbers of dementia cases in other demographic groups.

Vicky Garfield, another author on the paper, emphasized the need for broader confirmation. "We first need to replicate these results in other populations and ancestries to confirm the link and better understand the underlying biology," she said. The next steps for researchers include testing whether the association holds in more diverse populations and investigating what biological mechanism might explain why post-meal glucose spikes would increase dementia risk. Dung Trinh, an internist and chief medical officer of Healthy Brain Clinic who was not involved in the research, suggested that dementia prevention strategies might eventually incorporate glucose management alongside established risk factors like blood pressure, smoking, and physical activity. For now, the finding remains intriguing but unconfirmed—a signal that warrants investigation but not yet a basis for clinical action.